Pollio Fabrizio, Staibano Stefania, Mansueto Gelsomina, De Rosa Gaetano, Persico Francesco, De Falco Marianna, Di Lieto Andrea
Department of Obstetrical-Gynecological and Urological Science and Reproductive Medicine, University Federico II of Naples, Italy.
Hum Pathol. 2005 Jan;36(1):120-7. doi: 10.1016/j.humpath.2004.10.009.
The rare condition of women with erythrocytosis and a concurrent myomatous uterus has been classified as "myomatous erythrocytosis syndrome". Substantial myoma size has been noted as a common denominator in this condition in which recent evidence have confirmed erythropoietin (Epo) production by myoma tissues themselves. Apart from its primary endocrine role in controlling erythropoiesis, Epo has been demonstrated to mediate several cellular processes such as angiogenesis, mitogenesis, and inhibition of apoptosis by autocrine and paracrine mechanisms. Recently, Epo and its receptor (Epo-R) have been shown to be involved in the growth, viability, and angiogenesis of several malignant tumors including human female reproductive organ malignancies. In this paper, we researched on Epo and, as a first in the literature, Epo-R immunoexpression in a large uterine myoma of a term pregnant patient suffering from the myomatous erythrocytosis syndrome. Eight nongravidic leiomyomas and 8 gravidic leiomyomas were used as control group samples. Apart from confirming Epo production by myoma smooth muscle cells in the myomatous erythrocytosis syndrome, we reveal in this pathologic condition a characteristic strong Epo-R expression in myoma endothelial cells and a weak and sporadic Epo-R expression in myoma smooth muscle cells. The striking presence of Epo-R within myoma tissues in the case of the myomatous erythrocytosis syndrome allows us to speculate that myoma Epo production, besides determining erythrocytosis through systemic effects, may contribute, acting by autocrine and paracrine mechanisms, in determining the large myoma size almost always observed in this condition. Finally, we confirm a less but specific immunostaining for Epo in uterine myomas of patients without erythrocytosis and, as a first in the literature, we prove a weak and sporadic Epo-R expression in these lesions. These last results may contribute to knowledge of the yet unclear etiopathogenesis of the most common human gynecologic neoplasm.
患有红细胞增多症并伴有子宫肌瘤的罕见女性病症已被归类为“肌瘤性红细胞增多症综合征”。在这种病症中,肌瘤体积较大是一个共同特征,近期证据已证实肌瘤组织自身可产生促红细胞生成素(Epo)。除了在控制红细胞生成方面发挥主要内分泌作用外,Epo还通过自分泌和旁分泌机制介导多种细胞过程,如血管生成、有丝分裂和细胞凋亡抑制。最近,Epo及其受体(Epo-R)已被证明参与包括人类女性生殖器官恶性肿瘤在内的多种恶性肿瘤的生长、存活和血管生成。在本文中,我们研究了Epo,并且在文献中首次研究了患有肌瘤性红细胞增多症综合征的足月妊娠患者的大子宫肌瘤中Epo-R的免疫表达。选取8个非妊娠子宫肌瘤和8个妊娠子宫肌瘤作为对照组样本。除了证实肌瘤性红细胞增多症综合征中肌瘤平滑肌细胞产生Epo外,我们还发现在这种病理状态下,肌瘤内皮细胞中有特征性的Epo-R强表达,而肌瘤平滑肌细胞中Epo-R表达较弱且呈散在分布。在肌瘤性红细胞增多症综合征病例中,肌瘤组织内显著存在Epo-R,这使我们推测,肌瘤产生的Epo除了通过全身效应导致红细胞增多外,可能通过自分泌和旁分泌机制,促使肌瘤体积增大,而这种情况在该病症中几乎总是可见。最后,我们证实无红细胞增多症患者的子宫肌瘤中Epo免疫染色较弱但具有特异性,并且在文献中首次证明这些病变中有较弱且散在的Epo-R表达。这些最新结果可能有助于了解这种最常见的人类妇科肿瘤尚不清楚的病因发病机制。